Target
ABL Myristoyl Pocket
6 abstracts
Abstract
Disparities in frontline treatment and overall survival in the era of targeted tyrosine kinase inhibitor therapy for chronic myeloid leukemia: 2004-2021.Org: University of Utah, Huntsman Cancer Institute,
Abstract
ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): Primary results.Org: South Australian Health and Medical Research Institute, Universitätsklinikum Jena, Akita University Hospital, The University of Texas MD Anderson Cancer Center, University of Chicago,
Abstract
Pharmacokinetics and safety of asciminib (ASC) in pediatric patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP): Interim results from the ASC4KIDS study.Org: Novartis Institute for BioMedical Research, Kanagawa Children's Medical Center,
Abstract
A phase 2 clinical trial of regorafenib in patients with advanced pretreated melanoma (RegoMel).Org: Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel,
Abstract
Initial results from the phase (ph) 1 portion of a ph 1/2 study of THE-630 in patients (pts) with advanced gastrointestinal stromal tumor (GIST).Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Fox Chase Cancer Center, HonorHealth Research Institute, University of Miami Sylvester Comprehensive Cancer Center,
Abstract
Comparing GIST outcomes between geriatric and non-geriatric patients: A population-based analysis.Org: Worcester Academy, Northwell Health, New Hyde Park, NY, Northwell Heath,